RankAlpha logo
Back to Rankings

NMRA

Neumora TherapeuticsB
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
View Chart
Current thesis
Timely, informative NMRA-898 and NMRA-511 data plus NMRA-215's first-in-human transition could restore confidence in the post-navacaprant pipeline. Neumora reported $116.8 million of cash at June 30 and expected funding into the third quarter of 2027 [#SEC-8K-2026-08-14].
Posture
Constructive
Lead driver
Sentiment
What changed
Next scheduled catalyst: earnings 2026-11-04.
What can break
NMRA-898 and NMRA-511 data may be inconclusive or fail to translate into patient efficacy; NMRA-215 remains preclinical pending its planned IND [#SEC-8K-2026-08-14].
Momentum
98
Value
41
Sentiment
71
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.40 · Bull $0.80 · Bear $0.18Analysis 2026-10-07; returns require an exact persisted reference.
Earnings
2026-11-04
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-30 • Vendor: Data Vendor v1
Scores
As of 2026-10-30 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-07 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-10-30

Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-30. Definitions

Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $6.67
Why
Momentum98 · Δ7d -
Value41 · Δ7d +0.0
Sentiment71 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.

Confirming evidence

  • • Next scheduled catalyst: earnings 2026-11-04.
  • • Sentiment remains the lead driver in the composite.

Contradictions & invalidation

  • • NMRA-898 and NMRA-511 data may be inconclusive or fail to translate into patient efficacy; NMRA-215 remains preclinical pending its planned IND [#SEC-8K-2026-08-14].
  • • Second-quarter R&D expense was $29.3 million and net loss was $43.1 million. The stated cash runway into the third quarter of 2027 depends on the operating plan and does not eliminate future financing or dilution risk [#SEC-8K-2026-08-14].
  • • Navacaprant failed the primary and key secondary endpoints in KOASTAL-2 and -3, prompting discontinuation and an approximately 35% workforce reduction; the remaining programs are earlier-stage and carry substantial translation risk (June 15 SEC 8-K).

Catalyst clock

2026-11-04

NMRA-898 Phase 1 data

Lead driver: Sentiment · See AI snapshot
Momentum
98
8% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
47% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.2
Sentiment
71
45% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade

Composite grade B. Momentum 98.3 / Value 40.6 / Sentiment 70.6

Scenario snapshot

Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-07. Scenario method

B+
Bull case
20%
Probability
Target price
$0.80
Analysis reference price unavailable
Analysis 2026-10-07 · RankAlpha Sentiment Codex
Most likely
B
Base case
45%
Probability
Target price
$0.40
Analysis reference price unavailable
Analysis 2026-10-07 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$0.18
Analysis reference price unavailable
Analysis 2026-10-07 · RankAlpha Sentiment Codex
Fundamentals (TTM)
As of 2026-10-30
Market Cap
$69M
Beta
-
Shares Out
187.9M
P/E (TTM) · Derived
-0.3
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.35
Rev YoY
-
EPS YoY
-28.6%
Gross Margin
-
Op Margin
-
Net Debt
-$127.52M
Current Ratio
4.50
As of 2026-10-30 • Updated nightlySource: Internal modelMethods & Data